L3VLUP
ProSign in

INCY · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

INCYVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • INCY
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterINCYVRTX
Q3 202016 holders, $5.4bn31 holders, $21.9bn
Q4 202015 holders, $5.1bn30 holders, $18.4bn
Q1 202113 holders, $4.6bn31 holders, $15.4bn
Q2 202113 holders, $5.3bn30 holders, $12.7bn
Q3 202115 holders, $3.9bn35 holders, $10.1bn
Q4 202121 holders, $3.6bn28 holders, $12.4bn
Q1 202217 holders, $3.5bn23 holders, $16.1bn
Q2 202218 holders, $3.6bn25 holders, $18.1bn
Q3 202217 holders, $3.0bn22 holders, $18.4bn
Q4 202221 holders, $3.5bn28 holders, $18.4bn
Q1 202321 holders, $2.8bn26 holders, $21.4bn
Q2 202323 holders, $2.7bn27 holders, $24.7bn
Q3 202323 holders, $2.5bn33 holders, $24.3bn
Q4 202319 holders, $2.5bn32 holders, $28.6bn
Q1 202420 holders, $2.1bn31 holders, $29.8bn
Q2 202418 holders, $2.1bn29 holders, $33.4bn
Q3 202416 holders, $2.2bn27 holders, $33.5bn
Q4 202414 holders, $2.0bn26 holders, $28.5bn
Q1 202513 holders, $1.9bn21 holders, $35.4bn
Q2 202515 holders, $2.6bn21 holders, $32.3bn
Q3 202513 holders, $3.0bn22 holders, $25.9bn
Q4 202513 holders, $3.5bn26 holders, $31.8bn
Q1 202613 holders, $3.4bn25 holders, $31.8bn
Q2 202615 holders, $4.4bn26 holders, $34.6bn
INCY

Incyte Corp

Holders
14
Reported value
$2.0bn
Buyers
4
Sellers
9

Breadth -5 among 94 comparable managers.

Health care services and researchHealthcare: biopharma and medtech · L3VLUP
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only INCY (7)

Acadian Asset Management LLC, Bridgewater Associates LP, Caxton Associates LLP, Dodge & Cox, Freestone Grove Partners LP, Point72 Asset Management LP, Schonfeld Strategic Advisors LLC

Only VRTX (19)

AllianceBernstein LP, Artisan Partners LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →